Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.

被引：11
|
作者：
Higano, Celestia S.
Sternberg, Cora N.
Saad, Fred
Tombal, Bertrand F.
Miller, Kurt
Kalinovsky, Jan
Jiao, XiaoLong
Tangirala, Krishna
Sartor, A. Oliver
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Weill Cornell Med, Englander Inst Precis Med, New York, NY USA
[4] Univ Montreal, Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[5] Clin Univ St Luc, Brussels, Belgium
[6] Charite, Dept Urol, Berlin, Germany
[7] Bayer Healthcare Pharmaceut Inc, Basel, Switzerland
[8] Bayer Healthcare Pharmaceut Inc, Whippany, NJ USA
[9] Tulane Med Sch, New Orleans, LA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.256
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
256
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population
    Westgeest, H. M.
    Kuppen, M. C. P.
    van den Eertwegh, A. J. M.
    de Wit, R.
    Bergman, A. M.
    van Moorselaar, R. J. A.
    Coenen, J. L. L. M.
    van den Bergh, A. C. M.
    Somford, D. M.
    Mehra, N.
    van Oort, I. M.
    Aben, K. K. H.
    Gerritsen, W. R.
    Uyl-de Groot, C. A.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (03) : 871 - 879
  • [42] The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population
    H. M. Westgeest
    M. C. P. Kuppen
    A. J. M. van den Eertwegh
    R. de Wit
    A. M. Bergman
    R. J. A. van Moorselaar
    J. L. L. M. Coenen
    A. C. M. van den Bergh
    D. M. Somford
    N. Mehra
    I. M. van Oort
    K. K. H. Aben
    W. R. Gerritsen
    C. A. Uyl-de Groot
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 871 - 879
  • [43] Real-world analysis of prostate-specific antigen (PSA) outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA)
    Freedland, Stephen J.
    Schultz, Neil M.
    Coutinho, Anna D.
    Fuldeore, Rupali
    Hedlund, Nancy
    Feng, Qi
    Ramaswamy, Krishnan
    Hong, Agnes
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [44] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [45] Risk Factors for and Incidence of Seizures in Metastatic Castration-Resistant Prostate Cancer: A Real-World Retrospective Cohort Study
    Charles Dharmani
    Machaon Bonafede
    Andrew Krivoshik
    Clinical Drug Investigation, 2017, 37 : 1183 - 1190
  • [46] Risk Factors for and Incidence of Seizures in Metastatic Castration-Resistant Prostate Cancer: A Real-World Retrospective Cohort Study
    Dharmani, Charles
    Bonafede, Machaon
    Krivoshik, Andrew
    CLINICAL DRUG INVESTIGATION, 2017, 37 (12) : 1183 - 1190
  • [47] REAL-WORLD TREATMENT PATTERNS AND CARE PATHWAYS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
    Lam, J.
    Yang, C.
    Kaiser, C.
    Wong, W.
    VALUE IN HEALTH, 2018, 21 : S41 - S41
  • [48] Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
    Shore, Neal D.
    Laliberte, Francois
    Ionescu-Ittu, Raluca
    Yang, Lingfeng
    Mahendran, Malena
    Lejeune, Dominique
    Yu, Louise H.
    Burgents, Joseph
    Duh, Mei Sheng
    Ghate, Sameer R.
    ADVANCES IN THERAPY, 2021, 38 (08) : 4520 - 4540
  • [49] Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
    Neal D. Shore
    François Laliberté
    Raluca Ionescu-Ittu
    Lingfeng Yang
    Malena Mahendran
    Dominique Lejeune
    Louise H. Yu
    Joseph Burgents
    Mei Sheng Duh
    Sameer R. Ghate
    Advances in Therapy, 2021, 38 : 4520 - 4540
  • [50] Real-world evidence of treatment patterns and pharmacy costs among patients with metastatic castration-resistant prostate cancer (mCRPC) in a managed care population in the United States.
    Moses, Kelvin A.
    Wallace, Katrine
    Landsteiner, Adrienne
    Bunner, Scott
    Engel-Nitz, Nicole
    Lal, Lincy S.
    Golsorkhi, Anthony A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345